**Supplemental Table 1.** IMDC-related characteristics of patients (n = 77)

| Characteristic | No. (%) |
|---|---|
| Median time from ICI initiation to IMDC onset, days (IQR) | 103 (52-272) |
| Median duration of ICI treatment, days (IQR) | 83 (42-249) |
| Median duration of initial IMDC symptoms, days (IQR) | 56 (37-80) |
| Median Mayo endoscopic subscore (IQR) | 2 (0-3) |
| Overall median duration of steroid therapy for initial IMDC, days (IQR) | 38 (29-47) |
| Median number of steroid tapering attempts prior to SIT use (IQR) | 2 (1-3) |
| Type of SIT | |
|     Vedolizumab alone | 46 (60) |
|     Infliximab alone | 16 (21) |
|     Vedolizumab and infliximab combined | 15 (19) |

IMDC, immune-mediated diarrhea and colitis; ICI, immune checkpoint inhibitor; IQR, interquartile range; SD, standard deviation; SIT, selective immunosuppressive therapy.

**Supplemental Table 2.** Association between treatment of IMDC and differences in fecal calprotectin concentration between IMDC onset and last fecal calprotectin test following treatment of IMDC (n = 77)

| Characteristic | No. (%) | FC concentration, mcg/g Mean ± SD | *P*\* |
|---|---|---|---|
| Steroid therapy duration | | | 0.469 |
| ≤30 days | 23 (30) | 286 ± 39 | |
| >30 days | 54 (70) | 342 ± 73 | |
| Number of steroid tapering attempts | | | 0.623 |
| 1-2 | 56 (73) | 274 ± 64 | |
| ≥3 | 21 (27) | 313 ± 42 | |
| Number of SIT infusions | | | 0.033 |
| 1-2 | 25 (32) | 224 ± 54 | |
| ≥3 | 52 (68) | 379 ± 42 | |

FC, fecal calprotectin; IMDC, immune-mediated diarrhea and colitis; SD, standard deviation.

\*Based on unpaired *t* test for 2-group comparison.

**Supplemental Table 3.** Univariate logistic regression analysis of association of fecal calprotectin concentration with clinical, endoscopic, and histologic remission (n = 77)

| Outcome | OR (95% CI) | *P* |
|---|---|---|
| Clinical remission | 0.99 (0.98-1.00) | 0.051 |
| Endoscopic remission | 0.97 (0.96-0.99) | <0.001 |
| Histologic remission | 0.99 (0.98-1.01) | 0.056 |

OR, odds ratio; CI, confidence interval.

**Supplemental Table 4.** Predictive values of fecal lactoferrin for endoscopic and histologic remission (n = 64)

| Endpoint | Specificity | Sensitivity | NPV | PPV |
|---|---|---|---|---|
| Endoscopic remission, n=38 | 54% | 67% | 0.32 | 0.48 |
| Histologic remission, n=20 | 52% | 80% | 0.57 | 0.15 |

NPV, negative predictive value; PPV, positive predictive value.